By Fineline Cube 
Adagene Inc. (NASDAQ: ADAG) announced on September 16, 2025, that its collaboration and license agreement with Exelixis, originally signed in 2021, has been amended and expanded to include a third collaboration target. This expansion further leverages Adagene’s SAFEbody precision-masking technology platform.
Collaboration Details
Exelixis will utilize Adagene’s SAFEbody platform to develop a SAFE antibody-drug conjugate (SAFE-ADC) for the new target. Adagene is eligible to receive development and commercialization milestone payments, as well as royalties based on the product’s net sales.
Adagene’s Pipeline and Technology
Adagene, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cancer immunotherapies using its proprietary antibodies. Its lead candidate, ADG126, is in Phase Ib/II clinical study for metastatic microsatellite-stable colorectal cancer (MSS CRC), with plans to initiate a Phase II randomized trial by the end of 2025.-Fineline Info & Tech